Skip to main content
OpenTrials
Completed

NCT Number: NCT05447039

Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough

As of September 2020, the COVID-19 pandemic has affected millions of people in 196 countries and left hundreds of thousands dead. After recovery it was found that up to 32% of cases had 1 or 2 symptoms, 55% had 3 or more Post-COVID-19 symptoms, and persistent Post COVID-19 cough was recorded in 29.3% of cases in one study.

A recent study identified Montelukast, among the top-scoring clinically-oriented drugs likely to inhibit SARS-CoV-2 main protease. Besides its known effect that is reported to improve cough and prevent exercise-induced bronchoconstriction in asthma, many trials assessed Montelukast in the treatment of post-infectious cough and found variable effects.

Despite that the exact mechanism is not yet identified, Barré and colleagues proposed several properties of Cyst LT1 receptor antagonists that are potentially beneficial in COVID-19.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post Covid-19 Cough Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Signs and Symptoms, Respiratory

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aliae Mohamed-Hussein

Asyut, 71515, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with Post COVID-19 persistent cough after 4 weeks of acute attack

Exclusion criteria

  • Any contraindication to Montelukast, respiratory, cardiac disease, pregnancy, breastfeeding and use of angiotensin converting enzyme inhibitors.

Treatment and study plan

Montelukast Sodium Tablets

Drug

intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days

Other names: Montelukast

Primary outcomes

  1. cough severity index

    Time frame: 14 days

    Scale from mild to severe

  2. Cough severity visual analog

    Time frame: 14 days

    Severity from 0-10

Secondary outcomes

  1. Side effects of drug

    Time frame: 14 days

    Nausea, vomiting, abdominal pain, restlessness, depression

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough: A Randomized Controlled Pilot Study

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Jul 7, 2022
Registry last updated
Jul 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.